Pembrolizumab Yields Lasting Merkel-Cell Carcinoma Responses
April 20, 2016
Abstract
In a phase II single-arm study, the PD-1 checkpoint inhibitor pembrolizumab effectively shrank tumors and prolonged survival in more than half of patients with Merkel cell carcinoma. Responses were significantly more durable that those typically seen with chemotherapy.
View the clinical publicationThe authoritative source on Merkel cell carcinoma.
Last updated:
May 30, 2023
About the Disease
- What is a Merkel cell?
- What is Merkel cell carcinoma?
- Symptoms & appearance of Merkel cell carcinoma
- Causes of Merkel cell carcinoma
Testing & Diagnosis
Created in partnership with:
Seattle Multidisciplinary MCC Team, University of Washington MCC Research, Fred Hutchinson Cancer Research Center, and the Seattle Cancer Care Alliance/Skin Cancer